Latest "Puretech" News Stories

15:33 EDT 19th October 2018 | BioPortfolio

Here are the most relevant search results for "Puretech" found in our extensive news archives from over 250 global news sources.

More Information about Puretech on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Puretech for you to read. Along with our medical data and news we also list Puretech Clinical Trials, which are updated daily. BioPortfolio also has a large database of Puretech Companies for you to search.

Showing "Puretech" News Articles 1–25 of 68

Wednesday 17th October 2018

Karuna Appoints Jeff Jonas, M.D., to Board of Directors

Industry leader brings extensive experience in building and leading clinical development programs for central nervous system disorders Karuna Pharmaceuticals, Inc. (“Karuna”), focused on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders marked by psychosis and cognitive impairment, today announced the ...

Tuesday 16th October 2018

PureTech affiliate Karuna advances schizophrenia candidate

Karuna Pharmaceuticals, an affiliate of UK biopharma PureTech Health, has kicked off a Phase II study of KarXT, which is being developed for the treatment of psychosis in schizophrenia.

Monday 15th October 2018

Karuna Announces First Patient Dosed in Phase 2 Study of Lead Product Candidate KarXT for the Treatment of Schizophrenia

Phase 2 study aims to reproduce significant efficacy previously observed in schizophrenia trial with xanomeline alone Company also announces successful Phase 1 study of proprietary xanomeline and trospium chloride co-formulation, which will be used in Phase 2 study Karuna Pharmaceuticals, Inc. (“Karuna”), focused on target...

Thursday 4th October 2018

Vedanta Biosciences Announces Successful Phase 1a/1b Data Demonstrating Safety, Tolerability, and Proof of Mechanism for Lead, Rationally Defined Bacterial Consortium Product Candidate, VE303

All doses were safe and well-tolerated VE303 treatment resulted in rapid, durable, dose-dependent colonization and accelerated gut microbiota restoration after antibiotics A Phase 2 study in recurrent C. difficile infection is expected to begin in the fourth quarter of 2018 Three other programs in immuno-oncology, allergy, and in...

Monday 17th September 2018

PureTech Health Collaborator Publishes in Nature Neuroscience Highlighting Key Role of Brain Lymphatics in Neuroinflammatory Conditions Like Multiple Sclerosis

Work identifies junction between brain and lymphatics system, offering new insights into disease pathology Novel therapeutic approach to target neuroinflammation enabled by a deeper understanding of pathogenic immune cell trafficking between the CNS and the brain lymphatics Underlying intellectual property is exclusively licensed by PureT...

Thursday 13th September 2018

Puretech Health plc PRTC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09052018] Prices from USD $250

SummaryPuretech Health plc Puretech, formerly PureTech Ventures LLC is a biopharmaceutical company that develops medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company offers human proof of concept and pivotal stage programs. It develops a microbiome immune system drugdiscovery platform and drug candidates for immunemediated diseases; and pr...

Wednesday 12th September 2018

Akili Announces Exclusive Licensing Agreement for New Digital Technology Integrating Neural Systems Targeting and Physical Activity as Novel Cognitive Dysfunction Treatment Platform

Developed by leading neuroscientists at the U.C. San Francisco, currently in multiple clinical trials Technology is latest in series of new potential digital treatments Akili is pursuing Akili Interactive (“Akili” or “Company"), a leading prescription digital medicine company developing novel treatments

U.S. Department of Defense Awards $3.3 Million Grant to Alivio Therapeutics

Research award will support preclinical activities to advance product candidate for the treatment of interstitial cystitis/bladder pain syndrome into the clinic Alivio Therapeutics, an affiliate of

Monday 10th September 2018

Karuna closes $42mm Series A round to advance KarXT schizophrenia candidate

CNS-focused Karuna Pharmaceuticals Inc. (muscarinic receptors for psychiatric and cognitive disorders) raised $42mm in a Seri...

Wednesday 5th September 2018

PureTech’s Vedanta Biosciences adds Susan Dillon to Board of Directors

Vedanta Biosciences Appoints Susan Dillon, PhD, to Board of Directors

Former Global Head of Immunology at Janssen led development of multiple innovative therapies Vedanta Biosciences, a clinical stage company developing a new category of therapies for immune-mediated and infectious diseases based on rationally defined consortia of human microbiome-derived bacteria, today announced the appointment of industry ...

Thursday 30th August 2018

After many wonderful years at PureTech I am making a transition! Starting September 10 I'll be joining the team at Longwood Fund. I look back with fondness and forward with excitement.

After many wonderful years at PureTech I am making a transition! Starting September 10 I'll be joining the team at Longwood Fund. I look back with fondness and forward with excitement.

PureTech Founder Steinberg departs for Longwood Fund

Wednesday 15th August 2018

PureTech s Karuna appoints CEO

Karuna Names Former Voyager, Lilly Exec Steven Paul New CEO

Former Voyager Therapeutics (NASDAQ: VYGR) CEO Steven Paul has been tapped to run Boston-based Karuna Pharmaceuticals, a PureTech Health company that just raised $42 million this month. Karuna is developing a combination schizophrenia treatment that includes xanomeline, a drug it licensed from Eli Lilly (NYSE: LLY), where Paul was once head of R&D.

Karuna Appoints Seasoned Biopharma Veteran Steven Paul, M.D., as Chief Executive Officer

Former President of Lilly Research Laboratories and Co-founder of Sage and Voyager brings proven track record in neuroscience drug development Karuna founder, Andrew Miller, Ph.D., to serve as Chief Operating Officer Karuna Pharmaceuticals, Inc. (“Karuna”), focused on targeting musc

Thursday 9th August 2018

Akili Raises Additional $13 Million, Bringing Total Series C Funding to $68 Million

Akili Interactive (“Akili” or “Company"), a leading prescription digital medicine company developing novel treatments for cognitive dysfunction and brain-related conditions, has raised $13 million in new funding as an extension of its Series C financing, which was announced in May. The additional funds bring the total equity capital Akili has raised ...

Monday 6th August 2018

Video Analytics Market by Type Software and Services, Application Intrusion Management, Incident Detection, People/Crowd Counting, Traffic Monitoring, Deployment OnPremises and Cloud, Vertical, and Region Global Forecast to 2023 [Report Updated: 03052018

Government investments in emerging technologies to enhance public safety infrastructure and falling prices of video surveillance equipment are expected to drive the video analytics marketThe video analytics market size is expected to grow from USD 3.23 billion in 2018 to USD 8.55 billion by 2023, at a Compound Annual Growth Rate CAGR of 21.5% during the forecast period. Disadvantages of manual vid...

Thursday 2nd August 2018

PureTech Health’s Karuna Snags $42M Series A for Schizophrenia Drug

With $42 million in new investment, Karuna Pharmaceuticals, a PureTech Health company based in Boston, now has the funds to test in a Phase 2 clinical trial a drug for a disease where many have previously failed: schizophrenia. Karuna’s lead candidate, KarXT, is a combination of two compounds: xanomeline, licensed from Eli Lilly (NYSE: LLY), […]

Karuna completes $42 million financing round

Participants include ARCH Venture Partners, Wellcome Trust, PureTech Health, Steven Paul MD, and other undisclosed investors

Karuna Completes $42 Million Series A Financing Round to Advance Selective Muscarinic Receptor Agonist Program into Phase 2 Study

Participants include ARCH Venture Partners, Wellcome Trust, PureTech Health, Steven Paul M.D., and other undisclosed investors Karuna Pharmaceuticals, focused on targeting muscarinic receptors for the treatment of disorders marked by psychosis and cognitive impairment, today announced the completion of a $42 million Series A financing round, inc...

Sunday 29th July 2018

Perimeter Intrusion Detection Systems Market by Component Solutions and Services, Solutions Sensors Video Surveillance Systems, Services, Organization Size, Deployment Type, Vertical, and Region Global Forecast to 2023 [Report Updated: 06062018] Prices

Increasing installations of video surveillance for security systems is one of the most significant factors projected to drive the growth of the perimeter intrusion detection systems market.The perimeter intrusion detection systems market is estimated to be USD 10.73 billion in 2018 and is projected to reach USD 21.75 billion by 2023, at a CAGR of 15.2% during the forecast period. This growth can b...

Friday 27th July 2018

Life Science Executives and Investors Connect with Biotech Startups at BioPharm America™ Global Partnering Event this September

The eleventh annual BioPharm America™ will welcome over 700 global life science executives including pharma, established biotech, startups, and more investors than ever seeking strategic opportunities for new deals advancing

Thursday 26th July 2018

Roche Links with PureTech on Exosomes

Swiss pharmaceutical giant Roche has signed up to a multi-year collaboration with PureTech Health, a US clinical stage biopharma focused on the brain-immune-gut axis. The partners will advance PureTech’s milk-derived exosome platform technology for the oral administration of Roche’s antisense oligonucleotide platform.

Wednesday 25th July 2018

PureTech to use milk-derived exosomes to deliver Roche’s antisense therapies

In a multi-year deal, PureTech Health PLC will use its milk-derived exosome platform to develop oral delivery formulations of...

Quick Search


News Quicklinks